medroxalol , a new antihypertensive agent with alpha- and beta-adrenoreceptor blocking properties in both animals and humans , was administered in a single-blind study for 12 weeks to 29 patients with mild and moderate hypertension ( standing blood pressure : 188-130/130-100 mm hg ) .
C0001643
beta-adrenoreceptor
C0086418
humans